OncoMatch/Clinical Trials/NCT06859775
SHR-A1811 Combination Regimen for the Treatment of Recurrent or Metastatic Cervical Cancer
Is NCT06859775 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies multiple treatments for recurrent or metastatic cervical cancer.
Treatment: SHR-A1811 · Adebelimab · Bevacizumab · SHR-8068 · Cisplatin · Carboplatin — This study is a multicentre, open-label, dose-finding/efficacy-expanding phase Ib/II clinical trial to evaluate the tolerability, safety, pharmacokinetic profile and immunogenicity of SHR-A1811 combination regimen in the treatment of recurrent or metastatic cervical cancer and to preliminarily evaluate the efficacy of SHR-A1811 combination regimen for recurrent or metastatic cervical cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Chemotherapy
Other
Cancer type
Cervical Cancer
Disease stage
Metastatic disease required
Demographics
Lab requirements
Blood counts
Normal function of vital organs
Kidney function
Normal function of vital organs
Liver function
Normal function of vital organs
Cardiac function
Normal function of vital organs
Normal function of vital organs
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06859775 currently recruiting?
Yes, this trial is currently recruiting patients.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages